GORE VIABAHN VBX BALLOON EXPANDABLE ENDOPROSTHESIS
W. L. Gore & Associates, Inc. · Decision date Jan 27, 2017
What did the FDA approve?
The FDA approved the GORE VIABAHN VBX Balloon Expandable Endoprosthesis for treating de novo or restenotic lesions in iliac arteries. The stated reference vessel diameters range from 5 mm to 13 mm, with lesion lengths up to 110 mm, including lesions at the aortic bifurcation.
This record is an original PMA approval, not a supplement or manufacturing notice. The statement describes the approved indication as reported by the FDA; it does not independently establish safety or clinical effectiveness. No supplement type or supplement reason is supplied.
FDA approval order statement
Approval for the GORE VIABAHN VBX Balloon Expandable Endoprosthesis is indicated for the treatment of de novo or restenotic lesions found in iliac arteries with reference vessel diameters ranging from 5mm - 13mm and lesion lengths up to 110mm, including lesions at the aortic bifurcation.
- Regulatory pathway
- Original PMA
- Clinical specialty
- Cardiovascular
- Decision date
- Jan 27, 2017
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- P160021
- Regulatory pathway
- Premarket approval application
- Applicant
- W. L. Gore & Associates, Inc.
- Product code
- PRL
- Decision code
- APPR
- Decision date
- Jan 27, 2017
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Iliac covered stent, arterial.
- Applicant
- W. L. Gore & Associates, Inc.
- Product code
- PRL
- FDA device class
- 3
The approval statement above describes the scope recorded for this original decision. Later supplements may change the device or its indications.
FDA decision timeline
P160021 received
Application receipt date recorded by FDA.
P160021 · FDA decision
APPR
P160021/S051 · Related supplement
GORE VIABAHN VBX Balloon Expandable Endoprosthesis
Timeline entries are records held by MedtechLedger for P160021. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P160021
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| W. L. Gore & Associates, Inc. | PMA supplement | Oct 8, 2026 | FDA |
Regulatory context
An original PMA is a premarket approval application. The recorded approval scope is described in FDA’s order and supporting documents.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
W. L. Gore & Associates, Inc.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 3250 W. Kiltie Ln., Flagstaff, AZ, 86005
Sources and methodology
- Original FDA record: P160021
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records